anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
###  Impaired Liver Function

Do not use Xulane in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Discontinue Xulane if jaundice develops. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded. 

###  Liver Tumors

Xulane is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with CHC use. An estimate of the attributable risk is 3.3 cases/100,000 CHC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) CHC users. However, the risk of liver cancers in CHC users is less than one case per million users.
The utility model discloses a long-acting blood pressure reducing slowly-release degradation stick, which is characterized in that the long-acting blood pressure reducing slowly-release degradation stick comprises a small section of medical poly-caprolactone hose with degradability. The medical poly-caprolactone hose with degradability is filled with quantitative hypotensor and both ends of the poly-caprolactone hose are sealed by hot melt. The long-acting blood pressure reducing slowly-release degradation stick has simple structure, convenient manufacture and use, lasting effect and economy. The effect can last two years when the long-acting blood pressure reducing slowly-release degradation stick is embedded once. The medicine can be released slowly via the poly-caprolactone hose which is slightly hollow, the effective blood concentration can be guaranteed, the goal of steady reducing pressure is achieved, and the hose wall can be degraded within 2 to 3 years. The long-acting blood pressure reducing slowly-release degradation stick is suitable for various high blood pressures, reduces the trouble of a patient for long time of medicine taking and the phenomenon of a little high, a little low blood pressure resulting from forgetting to taking the medicine and taking the medicine at interval, and effectively prevents the diseases such as blood vessel of brain, etc. from happening.
PROBLEM TO BE SOLVED: To obtain a vaccine adjuvant for increasing immunogenicity of antigen by containing an emulsion of specific polymer and a glycopeptide. SOLUTION: This vaccine adjuvant is composed of an immunity-increasing glycopeptide and a nontoxic N,N,N',N'-tetra(polyoxypropylene- polyoxyethylene)-1,2-diaminoethane block polymer(tetrapolyol) and is an emulsion type having oily grains dispersed in a continuous water phase. When necessary, this emulsion is mixed with a nontoxic metabolic oily product, a surfactant basing on glycol ether and water. These adjuvant and vaccine are preferably administrated by intramusclar injection in an amount of 1-2ml. In this method, the validity of prescription is maintained, the physical stability is increased and the sensibility for refrigeration is decreased. Particularly, the validity of this adjuvant is maintained even in refrigerating.
Germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most common complications of the preterm newborn. The pathology of the GM-IVH is not completely understood and even regions distant from the lesion area are severely affected. It has been suggested that cerebellar diaschisis may underlie the neurodevelopmental problems that many of these kids show, including cerebral palsy, attention deficit disorders or hyperactivity. Additionally, GM-IVH has no successful treatment. VP3.15 is a dual action phosphodiesterase 7 (PDE7) and glycogen synthase kinase-3β (GSK-3β) inhibitor that limits neuroinflammation and neuronal loss. Therefore, it might also provide a relevant tool to reduce complications associated with GM-IVH. We have used a murine model of GM-IVH to analyze the short and long-term effects of VP3.15 in brain pathology and behavioral complications. In our hands, the induction of unilateral GM-IVH to P7 CD1 mice results in a short-term (P14) compromise of the cerebellar neuronal population and Purkinje cells arborization, an increase of microglia burden in the nuclei and an overall increase of punctuate cerebellar hemorrhages. Whereas brain alterations are no longer observed in the long term (P110), these animals present overt hyperactivity when analyzed in the adulthood, supporting the long-term behavioral impairment. Also, hyperactivity significantly correlates with ipsi and contralateral cerebellar sizes, neuronal densities and myelin basic protein levels. Importantly, treatment with VP3.15 significantly reduces neuronal loss, Purkinje cells simplification, the presence of cerebellar hemorrhages, as well as hyperactivity. Altogether, our data support the neuroprotective effects of VP3.15 in GM-IVH of the PT.
Intramedullary hip screw devices can be inserted with and without locking of the set screw, with the purpose of the set screw to minimize shortening of the femoral neck by rigidly positioning the head screw that inserts into the femoral head. Rigid locking of the lag screw may also limit the ability of the fracture fragments to compress against each other gradually with weight bearing and this potentially could reduce healing at the fracture site. Alternatively, more settling at the fracture site may allow more reliable healing while allowing more shortening of the femoral neck at the fracture site. Shortening of the femoral neck fracture can result in gait disturbances and poor hip function, while delay in healing can contribute to hardware failure and need for revision surgery. The benefit of placing the set screw in intramedullary hip screw fixation has not been clearly established in the literature. To date, there has been no study addressing this question, and the decision to lock, or not lock the screw is based on individual surgeon discretion. This study will help to clarify this decision point in the treatment of intertrochanteric hip fractures with the Intertan (Smith and Nephew, Memphis, Tn) intramedullary nail. This will lead to better patient outcomes, and help clarify the standard of care in these very common fracture patterns.

Subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will be randomized to undergo fixation with an intramedullary hip screw with and without locking of the set screw. These subjects will be blinded to the study group and will be treated as per standard of care after fixation of a hip fracture with xrays immediately after surgery, at 1-2 weeks, 6 weeks, and then 3 and 6 months post operatively. As per standard care additional xrays would be indicated until union of the fracture if there is delayed healing. Femoral neck shortening will be measured radiographically with femoral neck offset and the femoral neck shaft angle to be measured radiographically based on standardized computerized measurements from the xray images. TraumaCad software (Voyanthealth, Westchester, Il) will be utilized to obtain standardized measurements. A blinded subinvestigator will review the participants' x-rays and make the measurements required to determine the study outcomes. Time to radiographic union and any occurrence of hardware failure, nonunion and malunion will be noted. Demographic data including age, gender, smoking history, and medical comorbidities will be collected based on chart review. Subjective outcome scores (modified Harris hip score) will be collected at 3 and 6 months after surgery.
OBJECTIVE: To investigate pathways from micronutrient intake and serum levels to Chronic Oral Diseases Burden.
METHODS: We analyzed cross-sectional data from NHANES III (n = 7936) and NHANES 2011-2014 (n = 4929). The exposure was the intake and serum levels of vitamin D, calcium, and phosphorus. Considering the high correlation of those micronutrients in the diet, they were analyzed as a latent variable dubbed Micronutrient intake. The outcome was the Chronic Oral Diseases Burden, a latent variable formed by probing pocket depth, clinical attachment loss, furcation involvement, caries, and missing teeth. Pathways triggered by gender, age, socioeconomic status, obesity, smoking, and alcohol were also estimated using structural equation modeling.
RESULTS: In both NHANES cycles, micronutrient intake (p-value < 0.05) and vitamin D serum (p-value < 0.05) were associated with a lower Chronic Oral Diseases Burden. Micronutrient intake reduced the Chronic Oral Diseases Burden via vitamin D serum (p-value < 0.05). Obesity increased the Chronic Oral Diseases Burden by reducing vitamin D serum (p-value < 0.05).
CONCLUSION: Higher micronutrient intake and higher vitamin D serum levels seem to reduce Chronic Oral Diseases Burden. Healthy diet policies may jointly tackle caries, periodontitis, obesity, and other non-communicable diseases.
Improved physical activity (PA) and nutrition behaviors in adolescents show great promise to reduce risk of cancers and other diseases. Fewer than 20% of adolescents meet recommendations for fat or fruits \& vegetables consumption, and only 50% of adolescent girls and 67% of boys meet recommendations for vigorous PA. PACE+ will evaluate an integrated clinical and home-based intervention to improve physical activity (PA) and nutrition behaviors in adolescents. The intervention has three integrated components: a computer assessment and action planner; provider counseling; and 24 months of extended phone \& mail contact. 768 male and female adolescents age 11 through 15; will be recruited from six healthcare settings. Subjects will be randomly assigned within practices to two successive one-year "doses" of PACE+ or a comparison condition involving counseling for sun protection behaviors. PACE+ assesses four behaviors: 1) dietary fat, 2) fruits \& vegetable consumption, 3) physical activity, and 4) sedentary behavior. Primary behavioral outcomes, secondary outcomes, and selected mediators and process variables will be measured prior to the first office visit and at 6, 12 and 24 months. Primary outcomes will be measured by the 7-day physical activity recall and 3-day food record of fruits \& vegetables and fat at 12 months. Secondary outcomes include adiposity, fitness, BMI, psychosocial mediators of change, and body image. Potential risks are psychological and physical, however the risks are slight and of low likelihood. Benefits include helping bring about healthier lifestyles to prevent weight gain and reduce premature morbidity and mortality due to cancer, cardiovascular disease and other health problems. This study will be the first to evaluate a combined physical activity and nutrition intervention for youth that revolves around the primary health care setting.
PURPOSE:To prepare an antitumor substance, by extracting aloe with a hydrophilic organic solvent or its mixture with water, dialyzing or ultrafiltering the extract liquid, and collecting the dialyzate or ultrafiltrate. CONSTITUTION:Aloe (e.g. Aloe vera) is extracted with a hydrophilic organic solvent (e.g. methanol) or a mixture of a hydrophilic organic solvent and water, and the extract is dialyzed or ultrafiltered to obtain the objective antitumor substance as the dialyzate or the ultrafiltrate. Both aloctin A and B are high molecular weight component separated from aloe and having antitumor activity, and are found in the liquid left by dialysis or ultrafiltration, however, the dialyzate and the ultrafiltrate containing low molecular weight components are found to have excellent antitumor activity. The antitumor substance is preferably obtained by distilling out the solvent from the dialyzate or the ultrafiltrate, and pulverizing the residue. Effective dose: 1-100mg/kg daily.
A soap base, from which a cosmetic cream may be prepared by the addition of water, is produced by mixing an alkaline solution with saponifiable fat or fatty acid, heating the mixture with agitation at a temperature of 90 DEG  F. and then raising the temperature to 300-350 DEG  F. and maintaining the mixture at this temperature until a dry powder-like substance is formed.  The fat may be mixed in its liquid state with 5-15 per cent of a weak acid such as acetic acid and cooled before being mixed with the alkaline solution.  The alkaline solution may be 50 per cent aqueous potassium hydroxide. Oils such as almond oil, or cosmetic or therapeutic substances may be added during the final heating.ALSO:A soap base, from which a cosmetic cream may be prepared by the addition of water, is produced by mixing an alkaline solution with saponifiable fat or fatty acid, heating the mixture with agitation at a temperature of 90 DEG F, and then raising the temperature to 300-350 DEG F, and maintaining the mixture at this temperature until a dry powder-like substance is formed.  The fat may be mixed in its liquid state with 5-15 per cent of a weak acid such as acetic acid and cooled before being mixed with the alkaline solution.  The alkaline solution may be 50 per cent aqueous potassium hydroxide. Oils such as almond oil or cosmetic or therapeutic substances may be added during the final heating.
Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).
OBJECTIVES: To explore the evidence, urinary biomarkers, and partial mechanisms of hypercoagulability in the pathogenesis of IgA vasculitis (IgAV).
METHODS: Differential expression of proteins in the urine of 10 healthy children and 10 children with IgAV was screened using high-performance liquid chromatography-tandem mass spectrometry, followed by Reactome pathway analysis. Protein-protein interaction (PPI) network analysis was conducted using STRING and Cytoscape software. In the validation cohort, 15 healthy children and 25 children with IgAV were included, and the expression levels of differential urinary proteins were verified using enzyme-linked immunosorbent assay.
RESULTS: A total of 772 differential proteins were identified between the IgAV group and the control group, with 768 upregulated and 4 downregulated. Reactome pathway enrichment results showed that neutrophil degranulation, platelet activation, and hemostasis pathways were involved in the pathogenesis of IgAV. Among the differential proteins, macrophage migration inhibitory factor (MIF) played a significant role in neutrophil degranulation and hemostasis, while thrombin was a key protein in platelet activation and hemostasis pathways. PPI analysis indicated that thrombin directly interacted with several proteins involved in inflammatory responses, and these interactions involved MIF. Validation results showed that compared to healthy children, children with IgAV had significantly higher urine thrombin/creatinine and urine MIF/creatinine levels (P<0.05).
CONCLUSIONS: Thrombin contributes to the pathogenesis of IgAV through interactions with inflammatory factors. Urinary thrombin and MIF can serve as biomarkers reflecting the hypercoagulable and inflammatory states in children with IgAV.
PURPOSE: A pharmaceutical composition containing Poris cocos (Schw.) Wolf extract for suppressing multidrug resistance is provided to treat cancer patient with anticancer drug resistance. CONSTITUTION: A pharmaceutical composition for suppressing multi-drug resistance contains 0.001-50 wt% of Poris cocos (Schw.) Wolf extract as an active ingredient. The extract is prepared using water low carbon number alcohol of 1-4 carbon atoms, or a mixture solvent thereof. A pharmaceutical composition and a sitological composition for anticancer aid contain the extract as an active ingredient. The daily dose of the pharmaceutical composition is 0.001-100 mg/kg(body weight).
PURPOSE:To obtain a renal ischemia improving agent containing dichloroacetic acid and/or salt thereof as an active ingredient, capable of effectively improving renal blood flow in ischemia state and useful in prevention of renal failure. CONSTITUTION:At least one kind of dichloroacetic acid and/or salt thereof is added as an active ingredient and formulated according to a conventional method to provide the aimed product. The aimed product can be prepared in form of injection, tablet, granule, inhalant, ointment, suppository, etc. In the case of the injection, dichloroacetic acids are blended with distilled water for injection, diluent, stabilizing agent, etc. The amount of active ingredient contained in the injection is 0.5-20w/v% and dose thereof is 60-2500ml/adult.day. In the case of the oral agent, dichloroacetic acids are blended with diluting agent, binder, disintegrator, etc., and an amount of active ingredient contained in the agent is 1-70wt.% and dose thereof is 2-100mg/kg/day.
NEW MATERIAL:The compound of formula I (Y is group of formula II-VI). USE:Antitumor agent. PREPARATION:Streptomyces D788 (FERM-P No.7703) which is a baumycin- producing bacterial strain separated from soil, is inoculated and cultured in a medium. The culture liquid is collected and its pH is adjusted to 1.7 with concentrated sulfuric acid. The bacterial cells are separated from the culture liquid by filtering the liquid in the presence of a filter aid. The filtrate is passed through a column packed with a synthetic resin adsorbent to effect the adsorption of the product, washed with water, and eluted with 50% acetone water. The eluted liquid is concentrated under reduced pressure, adjusted to 8.5pH, extracted with chloroform, concentrated under reduced pressure, and precipitated with n-hexane. The precipitate is collected by filtration to obtain the objective compound of formula I.
The moisture retaining characteristic of cosmetics, dentifrices, hair preparations and ointments is increased by incorporating in such products a humectant which is a water-soluble hygroscopic salt of 2-pyrrolidone-5-carboxylic acid 2 - pyrrolidine - 4 - methyl - 5 - carboxylic acid, 1 - methyl - 2 - pyrrolidone - 5 - carboxylic acid, N - acetyl - glycine, N - acetyl - alanine or N - acetyl - 2 - amino - n - butyric acid, the amount of the humectant being at least 2% by weight of the total weight of the cosmetic or ointment and the humectant.  The salts are hydroscopic to the extent that the pure dry salts exhibit an increase of at least 30% by weight by absorption of moisture from the atmosphere when exposed at room temperature to air at 60% relative humidity.  Suitable salts are the sodium, potassium, ammonium and alkanolamine salts and mixtures thereof. Examples illustrate the incorporation of the humectants in a skin lotion, cream, cosmetic stick, suntan lotion and ointment base. Other products in which the humectants may be incorporated include dentifrice pastes, hair sprays, hair groom preparations, talcs, and body powders, cleansing creams, shaving creams, shaving powders and sticks, pre-shave lotions, deodorants and anti-perspirants.ALSO:The moisture retention by foods such as baked goods, fudge and chocolate candy is increased by incorporating a water-soluble hygroscopic salt of 2-pyrrolidone-5-carboxylic acid, 2-pyrrolidone-4-methyl-5-carboxylic acid, 1-methyl-2-pyrrolidone-5-carboxylic acid, N-acetyl glycine, N-acetylalanine or N-acetyl-2-amino-n-butyric acid, the amount of such humectant being at least 2% by weight.  The salts are hygroscopic to the extent that the pure dry salts exhibit an increase of at least 30% by weight at room temperature in air at 60% relative humidity.  Suitable salts are the sodium, potassium, ammonium and alkanolamine salts.
Initially, we will collect 30 patients with type 2 diabetes with a ≧ 3-month history of dyspeptic symptoms. An upper GI endocopy will be obtained to rule out possibility of organic obstruction. Cardiac arrhythmia and pregnancy will be excluded. None of them ever received abdominal surgery. Patients are then randomized to one of two treatment arms. Arm I: 15 patients received EA stimulation on acupoints St-36 (Zusanli) and Li-4 (Hegu). Arm II: 15 subjected to EA stimulation on non-acupoints around St-36 and Li-4 with the same electrical pulse and amplitude. Gastroparesis Cardinal Symptom Index (GCSI) and solid-phase gastric emptying time will be measured on baseline and after EA. In addition, serum gastrin, motilin, human pancreatic polypeptide, fasting blood sugar, and postprandial glucose levels will be also monitored.
Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure Aspects of the present disclosure provide pharmaceutical compositions comprising a population of particles coupled to a nicotinamide adenine dinucleotide (NAD) biosynthesis inhibitor. Other aspects of the present disclosure provide methods of local administration of a metabolic inhibitor, comprising locally administering a therapeutically effective amount of any of the pharmaceutical compositions described herein to a subject in need thereof. Other aspects of the present disclosure provide diagnostic methods comprising obtaining a sample from a subject; and detecting one or more mutations in a target nucleic acid in the sample; wherein the detecting is performed by isolating a nucleic acid comprising the target nucleic acid from the sample, and analyzing the nucleic acid for the presence of one or more allele-specific mutations; and wherein the detecting is performed in an intraoperative timeframe. Other aspects of the present disclosure provide methods of diagnosis and treatment of a cancer in a subject, comprising performing a surgical procedure on the subject; obtaining a sample from the subject; and determining whether the sample contains a one or more mutations in a target nucleotide sequence in the sample; wherein if the sample is determined to contain the one or more mutations, locally administering an agent with mutation selectivity to the subject during the surgical procedure. Other aspects of the present disclosure provide methods comprising performing any of the diagnostic methods described herein and performing any of the methods for local administration of an NAD biosynthesis inhibitor described herein. Yet other aspects of the present disclosure provide kits for the detection of mutant alleles.